Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2015

View Archived Issues

Clinical evidence of the utility of a new drug delivery system for the treatment of autism

New device shows potential for monitoring patients under OAT

Uncovering a drug-targetable proinflammatory pathway associated with acute respiratory syndrome

Dipraglurant demonstrates efficacy in multiple preclinical models

Azapeptide analogue exerts cardioprotective effects

Genmab enters into license agreement with Novo Nordisk for DuoBody technology

Neurocrine completes enrollment in phase III trial of NBI-98854

Bristol-Myers Squibb patents factor XIa and KLKB1 inhibitors

Allergan describes formyl peptide modulators

Roche to acquire GeneWEAVE BioSciences

Bayer Schering Pharma patent details antimitotic agents

Neuropore Therapies divulges ASYN aggregation inhibitors

AbbVie reports TrK-A inhibitors

Funding supports Biogazelle's work on long non-coding RNAs in cancer

Proteon initiates second phase III study of vonapanitase

FDA approves IND for Saniona's NS-2359 in the treatment of cocaine addiction

AXIM conducting clinical trials of MedChew RX chewing gum in Europe

Merck & Co. discloses novel series of BACE1 inhibitors for AD

First patients randomized in phase IIa trial of SER-150 in diabetic nephropathy

CDC exercises contract options for Emergent's VIGIV program

Phase II BIRCH study of atezolizumab meets primary endpoint

Phase I/II study of INV-103 in systemic lupus erythematosus complete

Onconova Therapeutics submits IND for new phase III study of intravenous rigosertib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...